Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma. | terminated | Phase 2 | 11 | Laval UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341725 | EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes Staging | terminated | — | 2 | Paolo Giorgio Arcidiacono, MDOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03958669 | Fingerprint Characterization Tyrosine Kinase Inhibitors in Advanced HCC(e:Med-HCC-2) | terminated | — | 2 | University Hospital TuebingenOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa(P2RX7) | terminated | N/A | 50 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | terminated | Early Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | terminated | N/A | 30 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | terminated | — | 11 | Columbia UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery(HSL2012-06) | terminated | — | 50 | Hospital Sirio-LibanesOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | terminated | N/A | 32 | Erasme University HospitalOTHER | 3 | Oct 23, 2023 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas(REGIRI) | terminated | Phase 1 / Phase 2 | 89 | UNICANCEROTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | terminated | Phase 2 | 9 | Baptist Health South FloridaOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib(PREMETHEP) | terminated | N/A | 61 | Centre Georges Francois LeclercOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04428437 | Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors | terminated | — | 17 | Humanity & Health Medical Group LimitedOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04106167 | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy | terminated | — | 20 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma(DEDUCTIVE) | terminated | Phase 1 / Phase 2 | 27 | AVEO Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 1 / Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects | terminated | Phase 2 | 73 | Antengene Therapeutics LimitedINDUSTRY | 3 | Jul 10, 2023 | clinicaltrials |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | terminated | Phase 3 | 355 | ECOG-ACRIN Cancer Research GroupNETWORK | 4 | Jul 6, 2023 | clinicaltrials |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC) | terminated | Phase 1 | 9 | Codiak BioSciencesINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03662841 | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma | terminated | N/A | 11 | Chinese University of Hong KongOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03808766 | A Study on the Angioarchitecture of Hepatocellular Carcinoma | terminated | N/A | 32 | Chinese University of Hong KongOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 1 | University of Texas Southwestern Medical CenterOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow Surrounding HAE | terminated | Early Phase 1 | 4 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | terminated | Early Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 12, 2024source: clinicaltrials